Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells

Journal of Radiation Research

Volumn 46, Issue 2, 2005, Pages 241-248

  Skvortsova, Ira ^a   Popper, Bela Andre ^a   Skvortsov, Sergej ^b   Saurer, Maria ^a   Auer, Thomas ^a   Moser, Robert ^c   Kamleitner, Hans ^a   Zwierzina, Heinz ^b   Lukas, Peter ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Apoptosis; Cell cycle; Non Hodgkin's lymphoma; Radiation; Rituximab

Indexed keywords

CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; GROWTH KINETICS; IONIZING RADIATION; MONOCLONAL ANTIBODIES; ONCOLOGY; RADIATION EFFECTS; RADIATION SHIELDING;

ANTIPROLIFERATIVE EFFECT; APOPTOTIC EFFECTS; CELL CYCLE; CYCLE DISTRIBUTION; LYMPHOMA CELLS; NON-HODGKIN LYMPHOMA; PRE-TREATMENTS; RADIATION-INDUCED; RAJI CELLS; RITUXIMAB;

CELL DEATH;

MONOCLONAL ANTIBODY; RADIOPROTECTIVE AGENT; RITUXIMAB; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECT; FOLLICULAR LYMPHOMA; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NONHODGKIN LYMPHOMA; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BURKITT LYMPHOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; NEOPLASM PROTEINS; RADIATION TOLERANCE; RADIATION-PROTECTIVE AGENTS;

EID: 23244450351     PISSN: 04493060     EISSN: None     Source Type: Journal    
DOI: 10.1269/jrr.46.241     Document Type: Article

References (28)

1. Pinkus, G. S. (1996) Needle biopsy in malignant lymphoma. J. Clin. Oncol. 14: 2415-2416.
2. Hainsworth, J. D. (2000) Monoclonal antibody therapy in lymphoid malignancies. The Oncologist. 5: 376-384.
3. The French Cooperative Group on Chronic Lymphocytic Leukemia (1990). A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood. 75: 1422-1425.
4. Multani, P. S. and Grossbard, M. L. (1998) Monoclonal antibody-based therapies for hematologic malignancies. J. Clin. Oncol. 16: 3691-3710.
5. Kunala, S. and Macklis, R. M. (2001) Ionizing radiation induces CD20 surface expression on human B cells. Int. J. Cancer (Radiat. Oncol. Invest.). 96: 178-181.
6. Boye, J., Elter, T. and Engert, A. (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann. Oncol. 14: 520-535.
7. Plosker, G. L. and Figgitt, D. P. (2003) Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Drugs. 63: 803-843.
8. Mellstedt, H. (2003) Monoclonal antibodies in human cancer. Drugs Today (Barc). 39 Suppl. C: 1-16.
9. Rose, A. L., Smith, B. E. and Maloney, D. G. (2002) Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 100: 1765-1773.
10. Reff, M. E., Carner, K., Chambers, K. S., Chinn, P. C., Leonard, J. E., Raab, R., Newman, R. A., Hanna, N. and Anderson, D. R. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 83: 435-445.
11. Harjunpaa, A., Junnikkala, S. and Meri, S. (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: direct compliment killing is superior to cellular effector mechanisms. Scand. J. Immunol. 51: 634-641.
12. Cartron, G., Watier, H., Golay, J. and Solal-Celigny, P. (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood. 104: 2635-2642.
13. Rose, A. L., Smith, B. E. and Maloney, D. G. (2002) Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood. 100: 1765-1773.
14. Shan, D., Gopal, A. K. and Press, O. W. (2001) Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells. Clin. Cancer. Res. 7: 2490-2495.
15. Ghetie, M. A., Bright, H. and Vitetta, E. S. (2001) Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 97: 1392-1398.
16. Di Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J. and Introna, M. (2001) Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol. 114: 800-809.
17. Alas, S., Ng, C. P. and Bonavida, B. (2002) Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin. Cancer Res. 8: 836-845.
18. Bezombes, C., Grazide, S., Garret, C., Fabre, C., Quillet-Mary, A., Muller, S., Jaffrezou, J. P. and Laurent, G. (2004) Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood. 104: 1166-1173.
19. Evans, H. H., Ricanati, M., Horng, M.-F., Jiang, Q., Mencl, J. and Oliver, P. DNA double-strand breaks rejoining deficiency in TK6 and other human B-lymphoblast cell lines. Radiat. Res. 134: 307-315.
20. Mustonen, R., Bouvier, G., Wolber, G., Stöhr, M., Peschke, P. and Bartsch, H. (1999) A comparison of gamma and neutron irradiation on Raji cells: effects on DNA damage, repair, cell cycle distribution and lethality. Mut. Res. 429: 169-179.
21. Sheen, J. H. and Dickson, R. B. (2002) Overexpression of c-Myc alters G(1)/S arrest following ionizing radiation. Mol. Cell Biol. 22: 1819-1833.
22. Yang, W., Shen, J., Wu, M., Arsura, M., FitzGerald, M., Suldan, Z., Kim, D. W., Hofmann, C. S., Pianetti, S., Romieu-Mourez, R., Freedman, L. P. and Sonenshein, G. E. (2001) Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 20: 1688-1702.
23. Enomoto, A., Suzuki, N., Kang, Y., Hirano, K., Matsumoto, Y., Zhu, J., Morita, A., Hosoi, Y., Sakai, K. and Koyama, H. (2003) Decreased c-Myc expression and its involvement in X-ray-induced apoptotic cell death of human T-cell leukaemia cell line MOLT-4. Int. J. Radiat. Biol. 79: 589-600.
24. Milner, A. E., Grand, R. J. A., Vaughan, A. T. M., Armitage, R. J. and Gregory, C. D. (1997) Differential effects of bcl-2 on survival and proliferation of human B-lymphoma cells following ã-irradiation. Oncogene. 15: 1815-1822.
25. Jazirehi, A. R., Gan, X. H., De Vos, S., Emmanouilides, C. and Bonavida, B. (2003) Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol. Cancer Ther. 2: 1183-1193.
26. CIP1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 419: 729-734.
27. Maclean, K. H., Keller, U. B., Rodriguez-Galindo, C., Nilsson, J. A. and Cleveland, J. L. (2003) C-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol. Cell Biol. 23: 7256-7270.
28. Duthu, A., Debuire, B., Romano, J., Ehrhart, J. C., Fiscella, M., May, E., Appella, E. and May, P. (1992) p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas. Oncogene. 7: 2161-2167.